330 related articles for article (PubMed ID: 16884450)
41. [Quetiapin in bipolar disorders].
Sümegi A
Neuropsychopharmacol Hung; 2008 Dec; 10(5):281-91. PubMed ID: 19419014
[TBL] [Abstract][Full Text] [Related]
42. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Rémillard S; Pourcher E; Cohen H
J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
[TBL] [Abstract][Full Text] [Related]
43. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
[TBL] [Abstract][Full Text] [Related]
44. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
[TBL] [Abstract][Full Text] [Related]
45. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases.
Stamouli S; Lykouras L
J Clin Psychopharmacol; 2006 Aug; 26(4):396-400. PubMed ID: 16855458
[TBL] [Abstract][Full Text] [Related]
46. Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.
Ereshefsky L; Tran-Johnson TK; Watanabe MD
Clin Pharm; 1990 Sep; 9(9):682-707. PubMed ID: 1977544
[TBL] [Abstract][Full Text] [Related]
47. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
Nikam SS; Awasthi AK
Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
[TBL] [Abstract][Full Text] [Related]
48. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
Kasper S
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
[TBL] [Abstract][Full Text] [Related]
49. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.
Weickert TW; Goldberg TE; Marenco S; Bigelow LB; Egan MF; Weinberger DR
Neuropsychopharmacology; 2003 Aug; 28(8):1491-500. PubMed ID: 12799617
[TBL] [Abstract][Full Text] [Related]
50. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
Widschwendter CG; Fleischhacker WW
Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
[TBL] [Abstract][Full Text] [Related]
51. [Neurobiology and treatment of mentalisation in schizophrenia].
Herold R; Tényi T
Neuropsychopharmacol Hung; 2005 Dec; 7(4):187-93. PubMed ID: 16496483
[TBL] [Abstract][Full Text] [Related]
52. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.
Wagner M; Quednow BB; Westheide J; Schlaepfer TE; Maier W; Kühn KU
Neuropsychopharmacology; 2005 Feb; 30(2):381-90. PubMed ID: 15578006
[TBL] [Abstract][Full Text] [Related]
53. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Miyamoto S; Duncan GE; Marx CE; Lieberman JA
Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
[TBL] [Abstract][Full Text] [Related]
54. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
Weiss EM; Bilder RM; Fleischhacker WW
Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
Lane HY; Lee CC; Liu YC; Chang WH
Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological treatment strategies for schizophrenia.
Lindenmayer JP; Khan A
Expert Rev Neurother; 2004 Jul; 4(4):705-23. PubMed ID: 15853589
[TBL] [Abstract][Full Text] [Related]
57. Antipsychotic medication and social cue recognition in chronic schizophrenia.
Roberts DL; Penn DL; Corrigan P; Lipkovich I; Kinon B; Black RA
Psychiatry Res; 2010 Jun; 178(1):46-50. PubMed ID: 20452678
[TBL] [Abstract][Full Text] [Related]
58. [Antipsychotics and memory functions in schizophrenic patients].
Brunnauer A; Geiger E; Laux G
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S158-60. PubMed ID: 15570539
[TBL] [Abstract][Full Text] [Related]
59. [Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment].
Glenthøj BY; Mackeprang T; Bille AE; Hemmingsen RP
Ugeskr Laeger; 1999 Mar; 161(10):1391-8. PubMed ID: 10085745
[TBL] [Abstract][Full Text] [Related]
60. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.
Horacek J; Bubenikova-Valesova V; Kopecek M; Palenicek T; Dockery C; Mohr P; Höschl C
CNS Drugs; 2006; 20(5):389-409. PubMed ID: 16696579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
